302 related articles for article (PubMed ID: 22941516)
1. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
[TBL] [Abstract][Full Text] [Related]
2. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.
Faisal N; Yoshida EM; Bilodeau M; Wong P; Ma M; Burak KW; Al-Judaibi B; Renner EL; Lilly LB
Ann Hepatol; 2014; 13(5):525-32. PubMed ID: 25152985
[TBL] [Abstract][Full Text] [Related]
5. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Antonini TM; Furlan V; Teicher E; Haim-Boukobza S; Sebagh M; Coilly A; Bonhomme-Faivre L; Roque-Afonso AM; Vittecoq D; Samuel D; Taburet AM; Duclos-Vallée JC
AIDS; 2015 Jan; 29(1):53-8. PubMed ID: 25387314
[TBL] [Abstract][Full Text] [Related]
6. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G
Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874
[TBL] [Abstract][Full Text] [Related]
7. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
8. Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Nair S; Waters B
Exp Clin Transplant; 2014 Apr; 12(2):117-22. PubMed ID: 24702143
[TBL] [Abstract][Full Text] [Related]
9. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
[TBL] [Abstract][Full Text] [Related]
10. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
[TBL] [Abstract][Full Text] [Related]
11. Current management and perspectives for HCV recurrence after liver transplantation.
Coilly A; Roche B; Samuel D
Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results.
Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
PLoS One; 2013; 8(11):e80528. PubMed ID: 24265827
[TBL] [Abstract][Full Text] [Related]
13. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy.
Verna EC; Shetty K; Lukose T; Terry N; Mentore K; Olsen SK; Fox AN; Dove LM; Brown RS
Liver Int; 2015 Feb; 35(2):510-7. PubMed ID: 24905624
[TBL] [Abstract][Full Text] [Related]
14. Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Lin CC; Kabiling C; Chen CL; Lin YH; Liu YW; Wang CC; Hu TH; Chiu KW
Transplantation; 2014 Apr; 97 Suppl 8():S47-53. PubMed ID: 24849835
[TBL] [Abstract][Full Text] [Related]
15. Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
O'Leary JG; McKenna GJ; Klintmalm GB; Davis GL
Liver Transpl; 2013 Apr; 19(4):463-5. PubMed ID: 23408534
[No Abstract] [Full Text] [Related]
16. Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Forns X; Didier S; Mutimer D; Fagiuoli S; Navasa M; Agarwal K; Berenguer M; Colombo M; Herzer K; Nevens F; Daems B; Janssen K; Ouwerkerk-Mahadevan S; Kimko H; Lathouwers E; Witek J; Van Solingen-Ristea R
Ann Hepatol; 2016; 15(4):512-23. PubMed ID: 27236150
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes.
Berenguer M; Ortíz-Cantó C; Abellán JJ; Aguilera V; Rubín A; Prieto M; López-Labrador FX
J Clin Virol; 2012 Mar; 53(3):231-8. PubMed ID: 22222052
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
[TBL] [Abstract][Full Text] [Related]
19. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
[TBL] [Abstract][Full Text] [Related]
20. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]